ELVN
Enliven Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.70
+3.70%Oct 14, 2026, 20:44 UTC
Enliven Therapeutics appointed Kristine Ball as a Class II director and Audit Committee member, with the appointment effective October 14, 2026.
Oct 6, 2026, 20:05 UTC
Enliven Therapeutics, Inc. announced that it reached alignment with the U.S. Food and Drug Administration on the final design of the ENABLE-2 Phase 3 trial of relcobatinib for previously treated chronic myeloid leukemia.
Source:Jun 15, 2026, 20:40 UTC
Enliven Therapeutics closed an upsized underwritten public offering of common stock and pre-funded warrants, including full exercise of the underwriters' option to purchase additional shares.
Source:Jun 11, 2026, 20:05 UTC
Enliven Therapeutics commenced an underwritten public offering of $250.0 million of shares of its common stock and pre-funded warrants.
Source: